DOCSLIB.ORG

Aggressive Lymphomas Michelle Wisniewski, PA Paul A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Aggressive Lymphomas Michelle Wisniewski, PA Paul A Nuances in the Management of Aggressive Lymphomas Michelle Wisniewski, PA Paul A. Hamlin, MD Memorial Sloan Kettering Cancer Center Learning Objectives 1. Demonstrate increased understanding of the mechanisms of action of targeted and immunotherapy agents in the treatment of primary and relapsed/refractory lymphomas, and their emerging role(s) in treatment regimens 2. Identify potential adverse events that may be associated with newer targeted and immunotherapies and how such adverse events may be adequately addressed to optimize patient outcome 3. Demonstrate an understanding of relevant clinical practice guidelines for lymphomas 4. Evaluate emerging treatment data in primary and relapsed/refractory lymphomas and its potential impact in clinical practice Financial Disclosure • Dr. Hamlin: • Consulting/Advisory Board: Genentech, Celgene, Gilead • Research Support: Seattle Genetics, Novartis, Molecular Templates, Portola, Janssen • Ms. Wisniewski has nothing to disclose. NHL Epidemiology in the United States • Most common hematologic cancer • Prevalence ~300,000 patients • ~80,900 new cases/year (2015) • ~20,940 deaths/year (2015) • From 2007–2011 NHL incidence rates increased slightly in men • Lifetime probability of developing NHL: 1:42 male, 1:52 female • Demographic shift accounts for most of increase NHL = non-Hodgkin lymphoma. American Cancer Society. Cancer Facts & Figures 2015, http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. WHO Classification of Lymphoid Neoplasms (2008) Precursor Indolent B Aggressive B Mature T/NK HL and PTLD • B lymphoBlastic leukemia/lymphoma • Chronic lymphocytic leukemia/ small • Mantle cell lymphoma • T-cell prolymphocytic leukemia • Hodgkin Lymphoma (HL) lymphocytic lymphoma • Diffuse large B-cell lymphoma • T-cell large granular lymphocytic leukemia • Nodular lymphocyte predominant • B lymphoBlastic leukemia/lymphoma, • B-cell prolymphocytic leukemia (DLBCL), NOS Hodgkin lymphoma NOS • Chronic lymphoproliferative disorder of NK-cells • Splenic marginal zone lymphoma • T-cell/histiocyte rich large B-cell • Aggressive NK cell leukemia • Classical Hodgkin lymphoma • B lymphoBlastic leukemia/lymphoma with lymphoma • Hairy cell leukemia • Systemic EBV positive T-cell lymphoproliferative • Nodular sclerosis classical Hodgkin recurrent genetic aBnormalities • Primary DLBCL of the CNS • Splenic lymphoma/leukemia, • disease of childhood lymphoma unclassifiable* • Primary cutaneous DLBCL, leg type • B lymphoBlastic leukemia/lymphoma with • Hydroa vaccineforme-like lymphoma • Lymphocyte-rich classical Hodgkin t(9;22)(q34;q11.2); BCR-ABL1 • Splenic diffuse red pulp small B-cell • EBV positive DLBCL of the elderly lymphoma lymphoma • Adult T-cell leukemia/lymphoma • DLBCL associated with chronic • Mixed cellularity classical Hodgkin • B lymphoBlastic leukemia/lymphoma with • Extranodal NK/T cell lymphoma, nasal type • Hairy cell leukemia-variant inflammation lymphoma t(v;11q23); MLL rearranged • Enteropathy-associated T-cell lymphoma • Lymphoplasmacytic lymphoma • Lymphomatoid granulomatosis • Lymphocyte depleted classical Hodgkin • B lymphoBlastic leukemia/lymphoma with• Waldenström’s macrogloBulinemia • Primary mediastinal (thymic) large B- • Hepatosplenic T-cell lymphoma lymphoma t(12;21)(p13;q22); TEL-AML1 (ETV6- • Heavy chain diseases cell lymphoma • SuBcutaneous panniculitis-like T-cell lymphoma • Post-Transplant Lymphoproliferative RUNX1) • Intravascular large B-cell lymphoma • Alpha heavy chain disease • Mycosis fungoides Disorders (PTLD) • B lymphoBlastic leukemia/lymphoma with • Gamma heavy chain disease • ALK positive large B-cell lymphoma • Sézary syndrome • Early lesions hyperdiploidy • Mu heavy chain disease • Plasmablastic lymphoma • Primary cutaneous CD30 positive T-cell • Large B-cell lymphoma arising in lymphoproliferative disorders • Plasmacytic hyperplasia • B lymphoBlastic leukemia/lymphoma with• Plasma cell myeloma HHV8-associated multicentric • Infectious mononucleosis-like PTLD hypodiploidy (hypodiploid ALL) • Solitary plasmacytoma of Bone • Lymphomatoid papulosis Castleman disease • Extraosseous plasmacytoma • Primary cutaneous anaplastic large cell lymphoma • Polymorphic PTLD • B lymphoBlastic leukemia/lymphoma with • Primary effusion lymphoma • Extranodal marginal zone lymphoma of • Primary cutaneous gamma-delta T-cell lymphoma • Monomorphic PTLD (B- and T/NK-cell t(5;14)(q31;q32); IL3-IGH • Burkitt lymphoma mucosa-associated lymphoid tissue • Primary cutaneous CD8 positive aggressive types) • B-cell lymphoma, unclassifiable, with • B lymphoBlastic leukemia/lymphoma with (MALT lymphoma) epidermotropic cytotoxic T-cell lymphoma • Classical Hodgkin lymphoma type t(1;19)(q23;p13.3); E2A-PBX1; (TCF3- • Nodal marginal zone lymphoma features intermediate between diffuse • Primary cutaneous CD4 positive small/medium T-cell PTLD large B-cell lymphoma and Burkitt PBX1) • Paediatric nodal marginal zone lymphoma lymphoma lymphoma • Peripheral T-cell lymphoma, NOS • T lymphoBlastic leukemia/lymphoma • B-cell lymphoma, unclassifiable, with • AngioimmunoBlastic T-cell lymphoma • Follicular lymphoma features intermediate between diffuse • Paediatric follicular lymphoma large B-cell lymphoma and classical • Anaplastic large cell lymphoma, ALK positive • Primary cutaneous follicle centre Hodgkin lymphoma • Anaplastic large cell lymphoma, ALK negative lymphoma ALL = acute lymphoBlastic leukemia; CNS = central nervous system; EBV = Epstein-Barr virus; HHV = human herpesvirus; NK = natural killer; NOS = not otherwise specified; WHO = World Health Organization. 2016 WHO Classification of Lymphoma Mature B-cell Neoplasms • Chronic lymphocytic leukemia /small lymphocytic lymphoma • Mantle cell lymphoma • Monoclonal B-cell lymphocytosis* • In situ mantle cell neoplasia* • B-cell prolymphocytic leukemia • Diffuse large B-cell lymphoma (DLBCL), NOS • Splenic marginal zone lymphoma • Hairy cell leukemia • Germinal center B-cell type* • Splenic B-cell lymphoma/leukemia, unclassifiaBle • Activated B-cell type* • Splenic diffuse red pulp small B-cell lymphoma • T cell/histiocyte-rich large B-cell lymphoma • Hairy cell leukemia-variant • Lymphoplasmacytic lymphoma • Primary DLBCL of the CNS • Waldenström macrogloBulinemia • Primary cutaneous DLBCL, leg type • Monoclonal gammopathy of undetermined significance (MGUS), IgM* • EBV positive DLBCL, NOS* • Mu heavy chain disease • EBV+ Mucocutaneous ulcer* • Gamma heavy chain disease • Alpha heavy chain disease • DLBCL associated with chronic inflammation • Monoclonal gammopathy of undetermined significance (MGUS), IgG/A* • Lymphomatoid granulomatosis • Plasma cell myeloma • Primary mediastinal (thymic) large B-cell lymphoma • Solitary plasmacytoma of Bone • Extraosseous plasmacytoma • Intravascular large B-cell lymphoma • Monoclonal immunogloBulin deposition diseases* • ALK positive large B-cell lymphoma • Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) • Plasmablastic lymphoma • Nodal marginal zone lymphoma • Primary effusion lymphoma • Pediatric nodal marginal zone lymphoma • Follicular lymphoma • HHV8 positive DLBCL, NOS* • In situ follicular neoplasia* • Burkitt lymphoma • Duodenal-type follicular lymphoma* • Burkitt-like lymphoma with 11q aberration* • Pediatric-type follicular lymphoma* • High grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 • Large B-cell lymphoma with IRF4 rearrangement* rearrangements* • Primary cutaneous follicle center lymphoma • High grade B-cell lymphoma, NOS* • B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma 2016 WHO Classification of Lymphoma Mature T and NK Neoplasms • Primary cutaneous CD4 positive small/medium T-cell lymphoproliferative disorder* • T-cell prolymphocytic leukemia • Peripheral T-cell lymphoma, NOS • AngioimmunoBlastic T-cell lymphoma • T-cell large granular lymphocytic leukemia • Follicular T-cell lymphoma* • Chronic lymphoproliferative disorder of NK cells • Nodal peripheral T-cell lymphoma with TFH phenotype* • Anaplastic large cell lymphoma, ALK positive • Aggressive NK cell leukemia • Anaplastic large cell lymphoma, ALK negative* • Systemic EBV+ T-cell Lymphoma of childhood* • Breast implant-associated anaplastic large cell lymphoma • Hydroa vacciniforme-like lymphoproliferative disorder* Hodgkin Lymphoma • Adult T-cell leukemia/lymphoma • Nodular lymphocyte predominant Hodgkin lymphoma • Extranodal NK/T-cell lymphoma, nasal type • Classical Hodgkin lymphoma • Nodular sclerosis classical Hodgkin lymphoma • Enteropathy-associated T-cell lymphoma • Lymphocyte-rich classical Hodgkin lymphoma • Monomorphic epitheliotropic intestinal T-cell lymphoma* • Mixed cellularity classical Hodgkin lymphoma • Lymphocyte-depleted classical Hodgkin lymphoma • Indolent T-cell lymphoproliferative disorder of the GI tract * • Hepatosplenic T-cell lymphoma Post-Transplant Lymphoproliferative Disorders (PTLD) • Plasmacytic hyperplasia PTLD • SuBcutaneous panniculitis-like T-cell lymphoma • Infectious mononucleosis PTLD • Mycosis fungoides • Florid follicular hyperplasia PTLD* • Sézary syndrome • Polymorphic PTLD • Monomorphic PTLD (B- and T/NK-cell types) • Primary cutaneous CD30 positive T-cell lymphoproliferative disorders • Classical Hodgkin lymphoma PTLD • Lymphomatoid papulosis Histiocytic and Dendritic Cell Neoplasms • Primary cutaneous anaplastic large cell lymphoma • Histiocytic sarcoma • Primary cutaneous gamma-delta T-cell lymphoma • Langerhans cell histiocytosis • Langerhans
Load more

Recommended publications
  • Lymphomatoid Papulosis and Recurrent Transitional Cell Carcinoma
    Volume 20 Number 4 April 2014 Letter Lymphomatoid papulosis and recurrent transitional cell carcinoma of the bladder: a paraneoplastic association WMS Leong1, CWD Aw1, KB Tan2 Dermatology Online Journal 20 (4): 17 1Division of Dermatology, National University Hospital, Singapore 2Department of Pathology, National University Hospital, Singapore Correspondence: Wai Mun Sean Leong, M.B.B.S. University Medicine Cluster National University Hospital 5 Lower Kent Ridge Road Singapore 119074 Phone: 67795555 Email: sean_wm_leong@nuhs.edu.sg Abstract Lymphomatoid papulosis is a rare, papulonodular skin eruption with histologic features of a CD30+ T cell lymphoma. We present a 79-year-old man with lymphomatoid papulosis and transitional cell carcinoma of the bladder. Introduction Lymphomatoid papulosis (LyP) is a rare, recurrent, self-healing papulonodular skin eruption with histologic features of a CD30+ malignant T cell lymphoma [1]. It belongs to a group of cutaneous CD30+ lymphoproliferative disorders, which includes cutaneous T cell lymphoma [2]. Patients with LyP are at risk of developing a second cutaneous or nodal lymphoma [3,4]. However, an association with transitional cell carcinoma (TCC) of the bladder has not been reported in the literature. This case illustrates a possible association between these two conditions. Case synopsis A 79-year-old man complained of a slightly itchy rash on the arms, neck, and shoulders for one year. Betamethasone- gentamicin cream previously afforded partial improvement. Approximately 9 months prior to presentation at the dermatology clinic, he was diagnosed to have TCC of the bladder (T1G3) and had undergone a trans-urethral resection of bladder cancer (TURBT) in December 2006 and January 2007.
    [Show full text]
  • Gamma Heavy Chain Disease Complicated by Pulmonary Hypertension, Which Was Successfully Treated with Lenalidomide Sho Shibata, Akiko Fukunaga
    BMJ Case Rep: first published as 10.1136/bcr-2020-236162 on 30 November 2020. Downloaded from Case report Gamma heavy chain disease complicated by pulmonary hypertension, which was successfully treated with lenalidomide Sho Shibata, Akiko Fukunaga Hematology, Tazuke Kofukai, SUMMARY with chemotherapy using the cyclophosphamide, Medical Research Institute, Heavy chain disease (HCD) is a rare B- cell proliferative vincristine and prednisone (CVP regimen), cyclo- Kitano Hospital, Osaka, Japan neoplasm that is characterised by the production of phosphamide, vincristine, doxorubicin and predni- truncated monoclonal immunoglobulin heavy chains sone (CHOP regimen), melphalan and bortezomib. Correspondence to without light chains. Gamma HCD is a subgroup of HCD. Lenalidomide, an immunomodulatory drug (IMiD), Dr Sho Shibata; ashitaharerukana21@ gmail. com A 67- year- old man was admitted to our hospital with has not yet been used in the treatment of gamma dyspnoea and lower leg oedema. Based on the results of HCD. We herein present a case of gamma HCD Accepted 2 November 2020 heart catheterisation, he was diagnosed with pulmonary complicated by pulmonary hypertension that hypertension. Laboratory tests revealed an elevated level showed a clinical response to lenalidomide. of IgG, and serum immunoelectrophoresis showed that IgG was a monoclonal gamma heavy chain without light CASE PRESENTATION chains. Finally, he was diagnosed with gamma HCD A- 67- year old man was admitted to our hospital complicated by pulmonary hypertension. Bortezomib with dyspnoea and lower leg oedema for 1 month. and dexamethasone therapy was initiated, but became He had a history of type 2 diabetes. On examina- refractory within 8 months. Therefore, the treatment was tion, his blood pressure was 163/88 mm Hg, pulse switched to lenalidomide and dexamethasone therapy, 97/min and respiratory rate 26/min with an O2 and the disease has been stably controlled for more saturation of 88% in room air, and he had spleno- than 2 years.
    [Show full text]
  • Comorbidities in Mycosis Fungoides and Racial Differences In
    medicines Article Comorbidities in Mycosis Fungoides and Racial Differences in Co-Existent Lymphomatoid Papulosis: A Cross-Sectional Study of 580 Patients in an Urban Tertiary Care Center Subuhi Kaul 1,*, Micah Belzberg 2, John-Douglas Matthew Hughes 3, Varun Mahadevan 2 , Raveena Khanna 2, Pegah R. Bakhshi 2, Michael S. Hong 2, Kyle A. Williams 2, 2 2, 2, Annie L. Grossberg , Shawn G. Kwatra y and Ronald J. Sweren y 1 Department of Medicine, John H. Stroger Hospital of Cook County, Chicago, IL 60612, USA 2 Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; mbelzbe@jhu.edu (M.B.); vmahade1@jhu.edu (V.M.); rkhanna8@jhmi.edu (R.K.); pb746@georgetown.edu (P.R.B.); michael.hong@som.umaryland.edu (M.S.H.); kwill184@health.fau.edu (K.A.W.); agrossb2@jhmi.edu (A.L.G.); skwatra1@jhmi.edu (S.G.K.); rsweren1@jhmi.edu (R.J.S.) 3 Section of Dermatology, University of Calgary, Alberta, AB T2N 1N4, Canada; jhugh017@uottawa.ca * Correspondence: subuhi.kaul@cookcountyhhs.org; Tel.: +1-312-864-7000 Considered co-senior authors. y Received: 26 October 2019; Accepted: 24 December 2019; Published: 26 December 2019 Abstract: Background: Mycosis fungoides (MF) is a cutaneous T-cell lymphoma. Previous reports have suggested MF is associated with inflammatory conditions such as psoriasis, increased cardiovascular risk factors as well as secondary neoplasms. Methods: A cross-sectional study of MF patients seen from 2013 to 2019 was performed. Comorbidities were selected based on the 2015 Medicare report highlighting the most common chronic medical illnesses in the United States.
    [Show full text]
  • Primary Cutaneous Anaplastic Large Cell Lymphoma / Lymphomatoid
    Primary Cutaneous CD30-Positive T-cell Lymphoproliferative Disorders Definition A spectrum of related conditions originating from transformed or activated CD30-positive T-lymphocytes May coexist in individual patients Clonally related Overlapping clinical and/or histological features Clinical, histologic, and phenotypic characteristics required for diagnosis Types 1. Primary cutaneous anaplastic large cell lymphoma (C-ALCL) 2. Lymphomatoid papulosis 3. Borderline lesions C-ALCL: Definition T-cell lymphoma, presenting in the skin and consisting of anaplastic lymphoid cells, the majority of which are CD30- positive Distinction from: (a) systemic ALCL with cutaneous involvement, and (b) secondary high-grade lymphomas with CD30 expression In nearly all patients disease is limited to the skin at the time of diagnosis Assessed by meticulous staging Patients should not have other subtypes of lymphoma C-ALCL: Synonyms Lukes-Collins: Not listed (T-immunoblastic) Kiel: Anaplastic large cell Working Formulation: Various categories (diffuse large cell; immunoblastic) REAL: Primary cutaneous anaplastic large cell (CD30+) lymphoma Related terms: Regressing atypical histiocytosis; Ki-1 lymphoma C-ALCL: Epidemiology 25% of the T-cell lymphomas arising primarily in the skin. Predominantly in adults/elderly and rare in children. The male to female ratio is 1.5-2.0:1. C-ALCL: Sites of Involvement The disease is nearly always limited to the skin at the time of diagnosis Extracutaneous dissemination may occur Mainly regional lymph nodes Involvement of other organs is rare C-ALCL: Clinical Features Most present solitary or localized skin lesions which may be tumors, nodules or (more rarely) papules Multicentric cutaneous disease occurs in 20% Lesions may show partial or complete spontaneous regression (similar to lymphomatoid papulosis) Cutaneous relapses are frequent Extracutaneous dissemination occurs in approximately 10% of the patients.
    [Show full text]
  • 18F-FDG Avidity in Lymphoma Readdressed: a Study of 766 Patients
    Journal of Nuclear Medicine, published on December 15, 2009 as doi:10.2967/jnumed.109.067892 18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients Michal Weiler-Sagie1, Olga Bushelev2, Ron Epelbaum2,3, Eldad J. Dann2,4,5, Nissim Haim2,3, Irit Avivi2,5, Ayelet Ben-Barak6, Yehudit Ben-Arie2,7, Rachel Bar-Shalom1,2, and Ora Israel1,2 1Department of Nuclear Medicine, Rambam Health Care Campus, Haifa, Israel; 2Ruth and Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel; 3Department of Oncology, Rambam Health Care Campus, Haifa, Israel; 4Blood Bank and Apheresis Unit, Rambam Health Care Campus, Haifa, Israel; 5Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; 6Department of Pediatric Hematology-Oncology, Meyer Children’s Hospital, Rambam Health Care Campus, Haifa, Israel; and 7Department of Pathology, Rambam Health Care Campus, Haifa, Israel PET/CT with 18F-FDG is an important noninvasive diagnostic tool for management of patients with lymphoma, and its use may sur- Lymphoma is a heterogeneous group of diseases rep- pass current guideline recommendations. The aim of the present resenting the fifth most common malignancy in the United study is to enlarge the growing body of evidence concerning 18F- FDG avidity of lymphoma to provide a basis for future guidelines. States, with an estimated 74,340 new cases predicted for Methods: The reports from 18F-FDG PET/CT studies performed 2008 (1). Subtypes of lymphoma differ in molecular char- in a single center for staging of 1,093 patients with newly diag- acteristics and biologic behavior. Based on clinical charac- nosed Hodgkin disease and non-Hodgkin lymphoma between teristics, this entity is divided into aggressive and indolent 2001 and 2008 were reviewed for the presence of 18F-FDG avid- types (2,3).
    [Show full text]
  • Landispiwowar.Kristin.Genetics of Select Lymphoproliferative
    3/21/16 Objecves Gene+cs of Select • Define tumor suppressor gene and oncogene Lymphoproliferave Neoplasms: • Correlate genotypes Pathophysiology, Prognos+caon, and Therapy with prognosis in lymphoproliferave neoplasms Kris+n Landis-Piwowar PhD, MLS(ASCP)CM • Recognize the targets of lymphoproliferave Clinical Laboratory Hematology, 3/E, McKenzie • Williams neoplasm therapies 2 Leukemia Lymphoma WHO 2008: Mature B-Cell Neoplasms • Chronic lymphocy+c leukemia/small lymphocy+c • Mantle cell lymphoma lymphoma • Diffuse large B-cell lymphoma (DLBCL), NOS • Primarily BM and • Primarily lymph • B-cell prolymphocyc leukemia • T-cell/his+ocyte rich large B-cell lymphoma • Primary DLBCL of the CNS • Splenic marginal zone lymphoma • Primary cutaneous DLBCL, leg type blood involvement node / solid ssue • Hairy cell leukemia • EBV-posi+ve DLBCL of the elderly • Splenic lymphoma/leukemia, unclassifiable • DLBCL associated with chronic inflammaon • Splenic diffuse red pulp small B-cell lymphoma • Lymphomatoid granulomatosis • Hairy cell leukemia variant involvement • Primary medias+nal (thymic) large B-cell lymphoma • Myeloid or • Lymphoplasmacy+c lymphoma • Intravascular large B-cell lymphoma • Waldenström macroglobulinemia • ALK-posi+ve large B-cell lymphoma lymphoid origin • Lymphoid origin • Heavy chain diseases • α Heavy chain disease • Plasmablas+c lymphoma • γ Heavy chain disease • Large B-cell lymphoma arising in HHV8-associated • May secondarily • May secondarily • μ Heavy chain disease mul+centric Castleman disease • Plasma cell myeloma • Primary
    [Show full text]
  • Successful Treatment of CD30+Lymphomatoid Papulosis
    ooggeenneessii iinn ss && rrcc aa MM CC uu tt ff aa Journal ofJournal of oo gg ll ee ee aa aa nn nn nn nn ee ee rr rr ss ss uu uu ii ii Watabe et al., J Carcinog Mutagen 2014, 5:3 ss ss oo oo JJ JJ ISSN: 2157-2518 CarCarcinogenesiscinogenesis & Mutagenesis DOI: 10.4172/2157-2518.1000174 Case Report Open Access Successful Treatment of CD30+Lymphomatoid Papulosis using a 308-nm Excimer Light Akiko Watabe, Taku Fujimura*, Sadanori Furudate and Setsuya Aiba Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan *Corresponding author: Taku Fujimura, Department of Dermatology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, 980-8574, Japan, Tel:+81 (22) 717-7271; Fax: +81 (22) 717-7361; E-mail: tfujimura1@mac.com Received date: Mar 11, 2014, Accepted date: May 03, 2014, Published date: May 07, 2014 Copyright: © 2013 Watabe A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Abstract We describe a 61-year-old Japanese patient with Lymphomatoid papulosis (LYP) successfully archived complete remission, using a 308-nm Excimer light. Interestingly, immunohistochemical staining revealed that CD30+ anaplastic tumor cells were surrounded by CD163+ macrophages and CCL18 producing cells, both of which were reported to correlate with the prognosis of CTCL. Our present study sheds light on the possible pathogenesis of LYP and the possibility of a 308-nm Excimer light phototherapy for LYP.
    [Show full text]
  • Lymphomatoid Papulosis Development in Acute Lymphoblastic Leukemia
    Case Report J Med Cases. 2021;12(8):306-309 Lymphomatoid Papulosis Development in Acute Lymphoblastic Leukemia Kazumi Ouraa, Tomonobu Satoa, d , Akihiro Iguchib, Naohisa Toriumic, Takeo Sarashinac Abstract LyP is a rare disease with an incidence of 1.2 - 1.9 per million [1] and accounts for 16.0-47.0% of pediatric cutaneous lym- Lymphomatoid papulosis (LyP) is a chronic, recurrent benign skin phoproliferative disorders [2]. It has been reported that LyP disease characterized by histological features of a CD 30-positive cu- often disappears spontaneously and has a benign course [3, taneous T-cell lymphoproliferative disorder. It is rare, with an annual, 4]. However, a relationship between LyP and certain hemato- worldwide incidence of 1.2 - 1.9 per million, and accounts for 16-47% logical malignancies has also been reported [5-7]. Herein, we of pediatric cutaneous lymphoproliferative disorders. It often occurs describe a case in which tumors appeared in the left scrotum on the extremities or the trunk and rarely affects the face or genitals. and under the left lip during maintenance therapy for pre- Its onset may be triggered by irradiation therapy, immunomodulating cursor B-cell acute lymphoblastic leukemia (BCP-ALL). We agents, infection or atopic dermatitis. It has a benign course but is as- needed to distinguish the tumor from extramedullary recur- sociated with certain hematological malignancies. Mycosis fungoides rence of ALL or de novo other cutaneous lymphoma; how- and primary cutaneous anaplastic large cell lymphoma are the most ever, the histological findings of a tumor biopsy resulted in a commonly associated hematological malignancies.
    [Show full text]
  • Co-Occurrence of Lymphomatoid Papulosis and Mycosis Fungoides in a Young Female: a Case Report Natalie Steinhoff, DO,* Brian Wanner,** Matthew H
    Co-Occurrence of Lymphomatoid Papulosis and Mycosis Fungoides in a Young Female: A Case Report Natalie Steinhoff, DO,* Brian Wanner,** Matthew H. Mahoney, MD*** *Dermatology Resident, PGY-3, Nova Southeastern University College of Osteopathic Medicine, Largo Medical Center, Largo, FL **Osteopathic Medical Student, 4th year, Des Moines University College of Osteopathic Medicine, Des Moines, IA ***Dermatologist and Clinical Faculty, Nova Southeastern University College of Osteopathic Medicine, Largo Medical Center, Largo, FL Disclosures: None Correspondence: Natalie Steinhoff, DO; NSUCOM/Largo Medical Center; 201 14th St. SW, Largo, FL 33770; nataliejsteinhoff@gmail.com Abstract There have been reports of lymphomatoid papulosis (LyP) and mycosis fungoides (MF) presenting separately, simultaneously, and consecutively. LyP is a CD30+ lymphoproliferative disorder, and MF is the most common cutaneous T-cell lymphoma (CTCL). LyP most often presents with self-regressing, erythematous-to-brown papules or small nodules. Mycosis fungoides has a variety of clinical manifestations, but in early stages it commonly presents as an erythematous patch or plaque. Recognizing LyP is important due to its association with development of secondary malignancies, most commonly MF, Hodgkin’s disease, and anaplastic large-cell lymphoma (ALCL). We report a case of a 35-year-old woman with recurrent LyP lesions since childhood who went on to develop concurrent LyP and MF. We discuss the need to evaluate LyP patients for secondary lymphomas and provide a concise review of the literature focusing on clinical presentation, diagnosis, disease associations, and management. microabscesses (mycosis cells in the epidermis), Spontaneous self-regression of lesions is required Introduction 3 19 Lymphomatoid papulosis (LyP) is one of two and a band-like dermal infiltrate of lymphocytes.
    [Show full text]
  • Lymphomatoid Papulosis in Children a Retrospective Cohort Study of 35 Cases
    STUDY Lymphomatoid Papulosis in Children A Retrospective Cohort Study of 35 Cases Tamar Nijsten, MD; Clara Curiel-Lewandrowski, MD; Marshall E. Kadin, MD Background: Lymphomatoid papulosis (LyP) is a rare of follow-up was 9.0 years. All included patients were con- entity, considered to be part of the spectrum of the CD30+ firmed by histologic examination. cutaneous lymphoproliferative disorders. About 10% to 20% of the adult LyP patients will develop an associated Results: The age distribution was significantly differ- lymphoid malignancy. Only a few cases of LyP have been ent, with boys having an earlier onset of LyP (P=.03). described in children, and the risk of associated lym- Of the 35 LyP patients, 3 (9%) developed a malignant phoid malignancies in these patients is not known. lymphoma; all were diagnosed as having non-Hodgkin lymphoma. Compared with the general population, pa- Objectives: To study the association between child- tients with childhood-onset LyP have a significantly in- hood onset of LyP and other malignancies and to deter- creased risk of developing non-Hodgkin lymphoma (rela- mine the clinical characteristics in this subgroup of pa- tive risk, 226.2; 95% confidence interval, 73.4-697.0). tients. More than two thirds of the patients reported being atopic, which is significantly more than the expected preva- Design: Retrospective cohort study. lence of atopy (relative risk, 3.1; 95% confidence inter- val, 2.2-4.3). Setting: Referral center at a university hospital. Retro- spective registry for patients with LyP of childhood on- Conclusions: Lymphomatoid papulosis presents simi- set (Յ18 years).
    [Show full text]
  • Laboratory Testing Requirements for Diagnosis and Follow-Up of Multiple Myeloma and Related Plasma Cell Dyscrasias
    Clin Chem Lab Med 2016; 54(6): 907–919 Review Maria A.V. Willrich* and Jerry A. Katzmann Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias DOI 10.1515/cclm-2015-0580 Received June 19, 2015; accepted September 15, 2015; previously Monoclonal gammopathies published online October 28, 2015 overview and categorization Abstract: Monoclonal immunoglobulins are markers of Immunoglobulins are produced by plasma cells, and plasma cell proliferative diseases and have been described clonal plasma cell proliferative diseases usually secrete as the first (and perhaps best) serological tumor marker. a monoclonal immunoglobulin (M-protein) that can The unique structure of each monoclonal protein makes be used as a serologic “tumor” marker. Because of this them highly specific for each plasma cell clone. The dif- secreted monoclonal immunoglobulin, these diseases are ficulties of using monoclonal proteins for diagnosing and also called monoclonal gammopathies. The secreted pro- monitoring multiple myeloma, however, stem from the teins can be used as a diagnostic tool for the identifica- diverse disease presentations and broad range of serum tion of the clone of plasma cells as well as a quantitative protein concentrations and molecular weights. Because of marker to follow the course of the disease and response to these challenges, no single test can confidently diagnose therapy. Unlike most serologic tumor markers, M-proteins or monitor all patients. Panels of tests have been recom- are extremely diverse. The M-proteins each have unique mended for sensitivity and efficiency. In this review we variable region sequences and the molecules may range discuss the various disease presentations and the use of from pentameric IgM (~900,000 Daltons) to monomeric various tests such as protein electrophoresis and immuno- free light chains (~24,000 Daltons).
    [Show full text]
  • Primary Cutaneous Lymphoma: ESMO Clinical Recommendations for Diagnosis, Treatment and Follow-Up R
    Annals of Oncology 19 (Supplement 2): ii72–ii76, 2008 clinical recommendations doi:10.1093/annonc/mdn095 Primary cutaneous lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up R. Dummer1 & M. Dreyling2 On behalf of the ESMO Guidelines Working Group* 1Department of Dermatology, University Hospital, Zu¨rich, Switzerland; 2Department of Medicine III, University Hospital Grosshadern, Munich, Germany introduction the quality of life due to their impact on skin appearance and annoying symptoms such as pruritus. In some cases they can Cutaneous lymphomas (CL) are the second most common already be disfiguring in early disease stages. In advanced stages, extranodal non-Hodgkin’s lymphomas. Their incidence is local skin problems are accompanied by systemic immune estimated at 1/100 000 yearly. Primary CL develop by definition suppression which results in an increased risk of infections and in the skin and remain confined to the skin for a long period of secondary malignancies. Some of the late-stage problems in time, while secondary CL reflect cutaneous spread from MF/SS patients might have been aggravated by earlier disseminated primary nodal or extranodal lymphomas. Primary therapeutic interventions, e.g. radiotherapy or phototherapy CL include a wide spectrum of clinically and histologically may contribute to mutations that increase the proliferative heterogeneous lymphoproliferative neoplasms: 75% of CL are and invasive capacity of the tumor cell populations. Cytotoxic cutaneous T-cell lymphomas (CTCL); 25% cutaneous B-cell drugs favor infectious complications. Most patients with lymphomas (CBCL); and a few percent other uncommon advanced disease may die due to secondary problems such as forms. CL and nodal or extracutaneous lymphomas with the infections.
    [Show full text]